Safety

Temodar (temozolomide) capsules and for injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

April 2015

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Infections and infestations: reactivation of infections such as cytomegalovirus and hepatitis B.
  • Endocrine disorders: Diabetes insipidus
     

 

May 2014

Summary View

5 WARNINGS AND PRECAUTIONS

5.5 Hepatotoxicity...section added
  • Fatal and severe hepatotoxicity have been reported in patients receiving TEMODAR. Perform liver function tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of TEMODAR.
6.2 Postmarketing Experience ... section edited

 

April 2010

Summary View 

ADVERSE REACTIONS

Postmarketing Experience
  • Cases of interstitial pneumonitis/pneumonitis, alveolitis, and pulmonary fibrosis have been reported.

 

Page Last Updated: 05/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.